Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has been selected as a B2i Digital Featured Company, highlighting its progress with the INTASYL® siRNA gene-silencing technology platform designed to enhance immune cell activity against cancer. The company's lead candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma.
In its Phase 1b trial, 22 patients completed treatment across five dose-escalation cohorts, including the final cohort at maximum dose concentration. The company reported no dose-limiting toxicities or serious adverse events, establishing a favorable safety profile. At the highest dose cohort, 6 of 7 patients responded, achieving 85% pathological response. Across all dosing cohorts in cSCC, Phio reported a pathological response rate of approximately 65%, with no disease progression observed among treated patients.
Phio has indicated that an FDA submission seeking guidance on next-stage clinical development is targeted for the second quarter of 2026. The company is advancing Chemistry, Manufacturing Controls and Toxicology fulfillment to satisfy future clinical registration trial requirements. As of its most recent update, Phio reported approximately $21.3 million in cash and cash equivalents, projected to sustain operations into the first half of 2027, supported by 2025 warrant inducement financings totaling approximately $12 million in net proceeds.
In February 2026, Phio strengthened its leadership team ahead of upcoming regulatory engagement and clinical milestones, promoting Lisa Carson to Chief Financial Officer and Jennifer Phillips, Pharm.D., to Senior Vice President, Regulatory and Corporate Affairs, and appointing Kimberly Man as Vice President of Program Development and Strategic Planning to support execution across PH-762 and PH-894. A dedicated Featured Company profile will be available at https://b2idigital.com/featured-companies.
"We are pleased to support Phio Pharmaceuticals as it advances a differentiated intratumoral immunotherapy platform in large skin cancer markets," said David Shapiro, Chief Executive Officer of B2i Digital. "The company has reported encouraging response data with a favorable safety profile, strengthened its leadership team, and is funded through key regulatory milestones."
"B2i Digital brings a focused approach to investor outreach," said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. "With favorable patient safety and pathology data, FDA engagement planned for 2026, and runway extending into 2027, we believe we are well positioned for the next stage of development."
In a February 10, 2026 research report, H.C. Wainwright & Co. reiterated its Buy rating and $14 price target on PHIO following the safety-efficacy update. The selection by B2i Digital, which connects investors and companies through digital marketing and investor conferences, provides Phio with enhanced visibility within the investment community as it approaches critical regulatory milestones. For additional information about Phio Pharmaceuticals, visit http://www.phiopharma.com.
